Skip to main content
. 2020 Oct 19;12(10):661. doi: 10.3390/toxins12100661

Table 8.

Overall rates of adverse events in Studies 1 and 2.

Placebo OnabotA
240 U
OnabotA
360 U
Number (%) of Patients
Study 1
Any AEs 28/36 (77.8%) 22/36 (61.1%) 26/36 (72.2%)
Treatment-related AEs 5/36 (13.9%) 6/36 (16.7%) 5/36 (13.9%)
Serious AEs 3/36 (8.3%) 1/36 (2.8%) 3/36 (8.3%)
Study 2
Any AEs 25/48 (52.1%) 30/52 (57.7%) 28/55 (50.9%)
Treatment-related AEs 4/48 (8.3%) 5/52 (9.6%) 7/55 (12.7%)
Serious AEs 7/48 (14.6%) 9/52 (17.3%) 6/55 (10.9%)

AE = adverse event.